ArticleJournal of substance use and addiction treatment2026
Validation of Medicaid claim-based opioid treatment program retention quality measures.
Article in Journal of substance use and addiction treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionUnderstanding the quality of care that opioid treatment programs (OTPs) deliver is a long-standing goal in the United States. In a prior study, this study team developed casemix adjusted OTP-level quality measures of patient retention that revealed a median 180-day OTP retention rate of 26% (25th percentile = 11%; 75th percentile = 37%) in Measurement Year (MY) 2023 (July 1, 2022 - June 30, 2023). The present study evaluated the measures' validity, particularly the association between each OTP's retention and their rate of substance use disorder (SUD) hospitalizations or emergency department (ED) visits, SUD-related mortality, and all-cause mortality.
methodsThis study used previously developed OTP retention measures derived from Medicaid claims data to ascertain patient retention for >30, >90, and >180 days. Using the same Medicaid claims data, the authors created measures of each OTP's rate of SUD hospitalizations or ED visits, SUD-related mortality, and all-cause mortality within 180 days of initiating treatment at an OTP. The authors assessed the validity of the OTP-level retention measures by estimating their rank-correlations with OTP-level SUD hospitalizations or ED visits, with SUD-related mortality, and with all-cause mortality, adjusted for patient casemix. Beta regression was used to assess the magnitude and direction of the associations between the retention measures and outcomes. Logistic regression tested whether episode-level retention predicted outcomes.
resultsThe sample included 1218 OTPs treating 268,003 newly initiating patients for 441,603 episodes in MY2023. Validity was indicated by negative correlations between OTP retention and SUD hospitalizations or ED visits and SUD-related mortality. Higher OTP retention was associated with lower odds of SUD hospitalizations or ED visits (OR 0.718, 95% CI 0.621-0.830 in MY2023 for >180-day retention) and SUD-related mortality (OR 0.675, 95% CI 0.471-0.968 in MY2020 for >180-day retention). Episode-level analyses confirmed these associations.
conclusionOTPs with higher retention had fewer negative outcomes after adjusting for patient casemix. These findings validate OTP-level retention as a quality indicator. Measuring OTP-level retention could support quality improvement efforts to increase retention in OTPs and reduce costly healthcare utilization related to opioid use disorder (OUD).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.